EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in PGD2/PTGDR2 signaling pathway in tumors: A review

Hengjin Tian, Kunpeng Ge, Lulu Wang, Peiyao Gao, Amin Chen, Feifan Wang, Fangzheng Guo, FengChao Wang, Qiang Zhang

Biomolecules and Biomedicine · 06.09.2024 · 24 (5) · 1055-1067

DOI: 10.17305/bb.2024.10485 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 06.09.2024. Verfasst von Hengjin Tian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China; Key Laboratory of Cancer Research and C…. Hauptthemen laut MEDLINE: Receptors, Prostaglandin, Prostaglandin D2, Signal Transduction, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Studies have shown that the prostaglandin (PG) family acts as an allergic inflammatory mediator in malignant diseases. Furthermore, prostaglandin E2 (PGE2) and its related receptors, as well as the prostaglandin D2 (PGD2)/PGD2 receptor (PTGDR2), play irreplaceable roles in tumorigenesis and anti-tumor therapy. Several experiments have demonstrated that PGD2 signaling through PTGDR2 not only directly inhibits cancer cell survival, proliferation, and migration but also reduces resistance toward conventional chemotherapeutic agents. Recent studies from our and other laboratories have shown that PGD2, its ligands, and related metabolites can significantly alter the tumor microenvironment (TME) by promoting the secretion of chemokines and cytokines, thereby inhibiting tumor progression. Additionally, reduced PGD2 expression has been associated with poor prognosis in patients with gastric, breast, lung, and pancreatic cancers, validating the preclinical findings and their clinical relevance. This review focuses on the current understanding of PGD2/PTGDR2 expression patterns and biological activity in cancer, proposing questions to guide the assessment of PGD2 and its receptors as potential targets for effective cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ProstaglandinProstaglandin D2Signal TransductionNeoplasmsTumor MicroenvironmentHumansAnimalsReceptors, Immunologic

Substanzen

Receptors, ProstaglandinProstaglandin D2prostaglandin D2 receptorReceptors, Immunologic

Autor:innen und Institutionen

  • Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China; Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China.
  • Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China.
  • Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
  • Department of Blood Transfusion, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Anhui Province Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical University, Bengbu, China.

Zitieren

APA

Tian, H., Ge, K., Wang, L., Gao, P., Chen, A., Wang, F., Guo, F., Wang, F., & Zhang, Q. (2024). Advances in PGD2/PTGDR2 signaling pathway in tumors: A review. Biomolecules and Biomedicine, 24(5), 1055-1067. https://doi.org/10.17305/bb.2024.10485

Vancouver

Tian H, Ge K, Wang L, Gao P, Chen A, Wang F, et al. Advances in PGD2/PTGDR2 signaling pathway in tumors: A review. Biomolecules and Biomedicine. 2024;24(5):1055-1067. doi:10.17305/bb.2024.10485

BibTeX
@article{Tian2024,
  author = {Tian, Hengjin and Ge, Kunpeng and Wang, Lulu and Gao, Peiyao and Chen, Amin and Wang, Feifan and Guo, Fangzheng and Wang, FengChao and Zhang, Qiang},
  title = {Advances in PGD2/PTGDR2 signaling pathway in tumors: A review},
  journal = {Biomolecules and Biomedicine},
  year = {2024},
  volume = {24},
  number = {5},
  pages = {1055--1067},
  doi = {10.17305/bb.2024.10485}
}
Kostenlos starten →